AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24642140
Drug: Healthy Directions
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy Directions 2 plus 2 brief telephone coaching calls (HD2+CC)
Trial: 24642247
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg intravenously approximately every 3 weeks over 30 minutes
Trial: 24643601
Drug: Fixed D-dimer
RxNorm normalized name: dimer dilinoleyl dimer dilinoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed D-dimer cutoff of 500 µg/L
Trial: 24646518
Drug: Oral 300,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral 300,000 units cholecalciferol administered at baseline and 8-weeks
Trial: 24646562
Drug: Hepatic-arterial infusion
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic-arterial infusion plus systemic chemotherapy including bevacizumab (Bev)
Trial: 24646562
Drug: Hepatic-arterial infusion
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic-arterial infusion plus systemic chemotherapy without bevacizumab (Bev)
Trial: 24647390
Drug: Homocysteine (μmol/L)
RxNorm normalized name: mecysteine
DrugBank: Homocysteine (DB04422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homocysteine (μmol/L)
Trial: 24649361
Drug: Intrathecal clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal clonidine 75 µg with bupivacaine (group C)
Trial: 24649361
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl 0.5 mL with bupivacaine (group F)
Trial: 24649361
Drug: Intrathecal distilled
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal distilled water 0.5 mL with bupivacaine (group P)
Trial: 24652992
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1.8 mg/kg administered every 3 weeks until progression or unacceptable toxicity
Trial: 24653510
Drug: Ezetimibe (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe (10 mg/d) + Atorvastatin (10 mg/d)
Trial: 24653510
Drug: Rosuvastatin (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (2.5 mg/d)
Trial: 24653520
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9% solution (control group)
Trial: 24653937
Drug: Levomilnacipran extended-release
RxNorm normalized name: levomilnacipran Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levomilnacipran extended-release 40-120mg/day
Trial: 24655871
Drug: Sliding scale
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sliding scale insulin to lower blood glucose levels (n = 145)
Trial: 24655871
Drug: No insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No insulin (n = 98)
Trial: 24661373
Drug: Patient controls
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controls (mRCC not receiving systemic treatment)
Trial: 24661784
Drug: C1 esterase
RxNorm normalized name: C1 esterase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1 esterase inhibitor concentrate (C1-INH) at 20 IU/kg
Trial: 24662454
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus cisplatin and vinorelbine (chemotherapy)
Trial: 24664935
Drug: TNFα antagonist
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TNFα antagonist therapy
Trial: 24665992
Drug: Defibrillator with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrillator with cardiac resynchronization therapy (n = 132)
Trial: 24667011
Drug: Sequential application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential application of four preventive measures
Trial: 24668831
Drug: Cryocontact therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cryocontact therapy
Trial: 24668858
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg orally three times a week
Trial: 24669960
Drug: IV rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV rt-PA treatment
Trial: 24670165
Drug: Ceritinib (LDK378)
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ceritinib (LDK378) at doses of 400 mg or more per day
Trial: 24670608
Drug: Temozolomide at
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide at 150 mg/m(2)/day on days 1-7 and days 15-21 during each 4-week cycle
Trial: 24670710
Drug: Totally subcutaneous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Totally subcutaneous implantable defibrillator (S-ICD)
Trial: 24671831
Drug: RP-1127 (glyburide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RP-1127 (glyburide for injection)
Trial: 24674873
Drug: Bosutinib at
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib at 400 mg/day plus exemestane at 25 mg/day
Trial: 24674873
Drug: Bosutinib at
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bosutinib at 300 mg/day plus exemestane at 25 mg/day
Trial: 24674874
Drug: Bosutinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib (400 mg/day) plus Letrozole (2.5 mg/day)
Trial: 24676282
Drug: Angiotensin converting
RxNorm normalized name: Angiotensin converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers
Trial: 24678902
Drug: Intravenous vinorelbine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vinorelbine 25 mg/m2 and cisplatin 80 mg/m2 on day 1 and oral vinorelbine 60 mg/m2 on day 8 for 2 induction cycles.
Trial: 24678902
Drug: Cisplatin 80
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 80 mg/m2 on day 1 and oral vinorelbine 20 mg on days 1, 3 and 5 during concomitant radiotherapy 2 Gy daily, 5 days/week for a total of 66 Gy.
Trial: 24682387
Drug: Impact of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Impact of physician and empirical estimates of bleeding on treatment choice
Trial: 24683529
Drug: Exercise intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exercise intervention (EX) - resistance bands, 3 times weekly during chemotherapy
Trial: 24684466
Drug: Teriparatide treatment
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide treatment for 18 months
Trial: 24684785
Drug: Everolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (5 mg daily) and Carboplatin (AUC 6, later decreased to AUC 5 and AUC 4) every 3 weeks
Trial: 24685375
Drug: Branched endograft
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched endograft treatment for arch aneurysms
Trial: 24685375
Drug: Branched endograft
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched endograft treatment for arch aneurysms (early experience group)
Trial: 24685605
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKA) in regular medical care
Trial: 24685605
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKA) in telemedicine-based coagulation service
Trial: 24685605
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonists (VKA) in both cohorts
Trial: 24687156
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents with biodegradable polymer
Trial: 24687156
Drug: Second-generation drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second-generation drug-eluting stents with durable polymer
Trial: 24687408
Drug: Low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemcitabine (250 mg/m²) in a 6-h infusion plus cisplatin (35 mg/m²) on days 1 and 8 every three weeks
Trial: 24687408
Drug: Low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose gemcitabine infusion plus cisplatin
Trial: 24688075
Drug: Standard-titer Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age
Trial: 24688075
Drug: Standard-titer Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age
Trial: 24688075
Drug: Standard-titer Edmonston-Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-titer Edmonston-Zagreb measles vaccine at 9 months of age, with or without a second dose at 18 months of age
Trial: 24691436
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (110 mg bid)
Trial: 24692579
Drug: Trabectedin 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.3 mg/m(2) as a 3-h i.v. infusion every 3 weeks until progression or intolerance
Trial: 24699474
Drug: ART (antiretroviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART (antiretroviral therapy)
Trial: 24699910
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4 mg/m² IV on days 1 and 8 of each 3-week cycle
Trial: 24703206
Drug: Beta-blockers (carvedilol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses of 50mg, 200mg, and 10mg/day respectively.
Trial: 24703206
Drug: Beta-blockers (carvedilol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers (carvedilol, metoprolol succinate, bisoprolol) at target doses.
Trial: 24704773
Drug: Asunaprevir 200
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 200 mg twice daily in mild hepatic impairment
Trial: 24704773
Drug: Asunaprevir 200
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 200 mg twice daily in moderate hepatic impairment
Trial: 24704773
Drug: Asunaprevir 200
RxNorm normalized name: asunaprevir
DrugBank: Asunaprevir (DB11586)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Asunaprevir 200 mg twice daily in severe hepatic impairment
Trial: 24705186
Drug: Radotinib 400
RxNorm normalized name: Radotinib
DrugBank: Radotinib (DB12323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radotinib 400 mg twice daily for 12 cycles
Trial: 24705975
Drug: Pazopanib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (400 or 600 mg daily)
Trial: 24705975
Drug: Pazopanib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (600 mg) on Day 15 with bevacizumab (7.5 mg/kg iv)
Trial: 24705975
Drug: Pazopanib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (600 mg) on Day 16 (24h after bevacizumab)
Trial: 24707402
Drug: H. pylori
RxNorm normalized name: H. PYLORI AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H. pylori eradication therapy (lansoprazole 30 mg twice daily, amoxicillin 0.75 g twice daily, clarithromycin 250 mg twice daily for 14 days)
Trial: 24708624
Drug: HLA-A*2402-restricted multi-peptide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HLA-A*2402-restricted multi-peptide vaccine combined with CRT (radiotherapy 60 Gy, cisplatin 40 mg/m², 5-fluorouracil 400 mg/m²)
Trial: 24708667
Drug: Alpha fetoprotein
RxNorm normalized name: Alpha fetoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha fetoprotein DNA prime and adenovirus boost vaccination (3 plasmid DNA injections followed by 1 AdV injection, all intramuscularly)
Trial: 24708726
Drug: Integrative Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative Medicine (IM) intervention at UAIHC
Trial: 24710768
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy plus cetuximab (weekly cetuximab plus 3-week cycles of cisplatin/5-FU for up to 6 cycles)
Trial: 24710768
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy plus cetuximab
Trial: 24710915
Drug: Diet emphasizing
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet emphasizing dietary pulse intake (median dose of 130 g/d)
Trial: 24711230
Drug: Progression risk
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progression risk score based on biological markers (CD38, ZAP-70, IGHV mutational status)
Trial: 24711549
Drug: Lapatinib (7,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (7,000 mg per day in twice-daily dosing)
Trial: 24711549
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of lapatinib
Trial: 24711551
Drug: hu14.18K322A (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hu14.18K322A (60 mg/m(2) per day for 4 days)
Trial: 24714268
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors administration
Trial: 24714750
Drug: Ombrabulin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (35 mg/m²) with docetaxel (75 mg/m²)
Trial: 24714750
Drug: Ombrabulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (30 mg/m²) with docetaxel (100 mg/m²)
Trial: 24714750
Drug: Ombrabulin (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (42 mg/m²) with docetaxel (75 mg/m²)
Trial: 24714750
Drug: Ombrabulin (35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (35 mg/m²) with docetaxel (100 mg/m²)
Trial: 24714750
Drug: Ombrabulin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (30 mg/m²) with docetaxel (75 mg/m²)
Trial: 24714750
Drug: Ombrabulin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ombrabulin (100 mg/m²) with docetaxel (100 mg/m²)
Trial: 24714973
Drug: Zalutumumab (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zalutumumab (weekly infusions, individually titrated to a grade 2 skin rash)
Trial: 24715548
Drug: Pioglitazone (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (15-30 mg/day) for 8 weeks
Trial: 24716469
Drug: GSK933776 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK933776 1 mg/kg
Trial: 24716469
Drug: GSK933776 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK933776 3 mg/kg
Trial: 24716469
Drug: GSK933776 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK933776 6 mg/kg
Trial: 24716542
Drug: Nab-paclitaxel (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nab-paclitaxel (260 mg/m² i.v. on day 1 of each 21-day cycle)
Trial: 24716655
Drug: Florbetapir F
RxNorm normalized name: Florbetapir F18
DrugBank: Florbetapir F-18 (DB09149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Florbetapir F 18 (amyloid imaging agent)
Trial: 24717109
Drug: Ocaratuzumab 375
RxNorm normalized name: Ocaratuzumab
DrugBank: Ocaratuzumab (DB17359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ocaratuzumab 375 mg/m(2) weekly for 4 weeks
Trial: 24717362
Drug: 25-hydroxyvitamin D
RxNorm normalized name: 25-hydroxyvitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxyvitamin D (25(OH)D) ≥ ∼26 μg/L (65.0 pmol/L)
Trial: 24717379
Drug: Lithium in
RxNorm normalized name: Product containing lithium in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium in monotherapy
Trial: 24717379
Drug: Prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic medication changed by psychiatrist
Trial: 24717379
Drug: Prophylactic medication
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic medication stopped by patient
Trial: 24717623
Drug: Lower respiratory
RxNorm normalized name: tissue respiratory factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower respiratory consultations with a course of antibiotics or oral steroids
Trial: 24720900
Drug: Genetically modified
RxNorm normalized name: Genetically modified virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically modified dendritic cells in combination with Cytokine-Induced Killer Cell treatment (gmDCs-CIK)
Trial: 24721800
Drug: Intravenous propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous propranolol and atropine
Trial: 24722222
Drug: Adults younger
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults younger than 55 years with severe burn injuries and inhalation injury
Trial: 24723428
Drug: Active medical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medical therapy for GERD (n = 49)
Trial: 24723493
Drug: Pentostatin, alemtuzumab,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentostatin, alemtuzumab, and low-dose high-frequency rituximab
Trial: 24723677
Drug: Low-dose plerixafor
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose plerixafor treatment
Trial: 24725395
Drug: rHuIL-12 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuIL-12 at doses of 2, 5, 10, 12, and 15 μg; 20 μg in the FIH study; 12 μg in the phase 1b expansion study.
Trial: 24726214
Drug: Atypical embryo
RxNorm normalized name: human embryo tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical embryo phenotypes (AS, A1(cyt), AC, CC)
Trial: 24726680
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg once daily for 7 days
Trial: 24726680
Drug: HCTZ 25
RxNorm normalized name: HCTZ 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg once daily for 28 days
Trial: 24726680
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days
Trial: 24732325
Drug: Low-dose non-adjuvanted
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose non-adjuvanted intradermal (ID) vaccine
Trial: 24732325
Drug: Full-dose MF59-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose MF59-adjuvanted intramuscular (IM) vaccine
Trial: 24732325
Drug: Full-dose MF59-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose MF59-adjuvanted IM vaccine
Trial: 24732325
Drug: Low-dose non-adjuvanted
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose non-adjuvanted ID vaccine
Trial: 24733245
Drug: Ibuprofen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (oral route, median dose of 10.0 mg/kg; range 3.4-11.4 mg/kg)
Trial: 24733245
Drug: Ibuprofen (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (oral route)
Trial: 24733463
Drug: Posaconazole i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole i.v. 200 mg q.d.
Trial: 24733463
Drug: Posaconazole i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole i.v. 300 mg q.d.
Trial: 24733473
Drug: AVP-21D9 (anthrax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVP-21D9 (anthrax monoclonal antibody)
Trial: 24733796
Drug: Trastuzumab emtansine
RxNorm normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab emtansine (T-DM1) 3.6 mg/kg plus pertuzumab (840-mg loading dose, then 420 mg subsequently) every 3 weeks
Trial: 24737778
Drug: Tivantinib 360
RxNorm normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tivantinib 360 mg b.i.d. with gemcitabine 1000 mg/m(2) weekly for 3 of 4 weeks